Crossmark

Whole exome sequencing analysis of a patient with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions with ETV6::LYN fusion gene

Crossref DOI link: https://doi.org/10.1007/s00277-024-06135-7

Published Online: 2024-12-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hosoba, Rika

Fukuhara, Suguru

Kogure, Yasunori

Takano, Kosuke

Shibata, Maki

Horiuchi, Toshikatsu

Kobayashi, Shinichi

Makita, Shinichi

Iwaki, Noriko

Munakata, Wataru

Maeshima, Akiko Miyagi

Kimura, Fumihiko

Kataoka, Keisuke

Izutsu, Koji
Funding

Funding for this research was provided by:

Otsuka Pharmaceutical Co. Ltd

Bristol Myers Squibb Co., Ltd.
License Information

Text and Data Mining valid from 2024-12-20

Version of Record valid from 2024-12-20
More Information

Article History

Received: 1 May 2024

Accepted: 2 December 2024

First Online: 20 December 2024

Declarations

:

: S.F. received honoraria from Otsuka Pharmaceutical Co. Ltd. S.M. received honoraria from Bristol Myers Squibb Co., Ltd. K.K. received research funding and honoraria from Otsuka Pharmaceutical Co. Ltd. K.I. received research funding, consulting fees, and honoraria from Bristol Myers Squibb Co., Ltd. The other authors declare no competing financial interests.

: Informed consent was obtained from the patient for publication.

: The authors declare no competing interests.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below